The 6-lymphocyte-restricted adhesion protein CD22 mediates sialic acid-dependent cell-cell interactions. Engagement of CD22 on B lymphocytes with a CD22 monoclonal antibody (MoAb) H622.7 that blocks the binding of CD22 to its ligand(s) directly stimulated 6-cell proliferation. In addition, the HB22.7 MoAb costimulated 6-cell proliferation with either anti-lgM, interleukin-2 (IL-2). IL-4, or CD40 and triggered predominantly B-cell IgG secretion with IL-2. Even more striking levels of B-cell proliferation occurred with HB22.7 MoAb under culture conditions that enhanced B-6-cell interactions. In contrast, a nonblocking CD22 MoAb (CD22.5) poorly costimulated in similar experiments. The functional D22 IS a B-lymphocyte-specific membrane protein.'
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ities, the genes that encode these proteins all map to chromosome 19q in humans and to the syntenic region on chromosome seven in This region of the human genome also contains CEA and a cluster of CEA-related genes.'' As noted above, CEA and many of the CEA-related genes also share some homology with CD22.
The other avenue of investigation that arose from analysis of the primary structure of CD22 focused on its intracellular portion. Within it are six tyrosines, four in two regions homologous to the ARH-1 or ITAM Phosphorylation of the tyrosines within an ITAM motif facilitates its interactions with the SH-2 domains of effector molecules. Several important lymphocyte signaling molecules contain this motif including the intracellular portions of the B-cell antigen receptor-associated molecules mb-1 and B29, and the T-cell antigen receptor associated molecules CDE, CD36, and CD3y. '8,19 Several pieces of evidence suggest that these ITAM-like regions in CD22 are functionally significant. Engagement of the B-cell antigen receptor or direct engagement of CD22 with an MoAb triggers CD22 tyrosine phosphorylation.*'-'' Likely because of this tyrosine phosphorylation increased amounts of p72syk, p85PI-3 kinase, and p53/p561yn associate with CD22.'Zd The use of tyrosine-phosphorylated synthetic peptides mapped the region of CD22 that likely mediates the associations of p53/561yn and p72syk to the distal ITAM-like motif (amino acids 822 to 842).""
In this study, we show that engagement of CD22 with an
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MoAb that blocks the interaction between CD22 and CD22L potently stimulates B lymphocytes and augments signals delivered via the B-cell antigen receptor complex, CD40, and two cytokine receptors. In addition, the availability of the CD22 blocking MoAb allowed a direct test of the potential importance of CD22KD22L interactions in T-cell activatiodproliferation.
MATERIALS AND METHODS
The MoAb HB22.7 (yZh,u) and CD22.5 (HD239, yZb; Fifth International Workshop on Human Leukocyte Differentiation Antigens, Boston, MA) have been previously d e~c r i b e d .~.~ Both antibodies interact with the N-terminal Ig domains of CD22, but CD22.5 does not bind in a ligand-binding region. The antibodies gave similar results when used for immunofluorescent staining of tonsil B cells or B-cell lines (data not shown). The CD22 polyclonal antiserum was prepared in rabbits using keyhole limpet hemocyanin conjugated with the peptide AWENVDYNILKH, whose sequence was derived from the COOH-terminus of human CD22. The CD3 MoAb was a kind gift of Dr Scott Koenig (Medimmune, Gaithersburg, MD). The HlF6 MoAb was used as an isotypematched control for the Ig production assays. This antibody is a purified MoAb produced against activated B cells and does not significantly affect B-cell proliferation or Ig production (J. Tuscano, et al, manuscript in preparation). Purity of tonsil B cells was monitored by CD20 immunofluorescence (CD20-FITC; Becton Dickinson Immunocytochemistry Systems, Mountain View, CA) using singlecolor cytofluorometry on an EPICS profile I (Coulter, Hialeah, FL). Ten thousand events were accumulated and analyzed for fluorescence.
Normal B and T lymphocytes were isolated from human tonsils. The tonsil B cells and T cells were purified as previously described.2' The RAMOS cell line was obtained from the American Type Culture Collection (ATCC; Rockville, MD) and maintained in continuous culture in RPMI 1640 plus 10% fetal calf serum (FCS; GIBCO-BRL, Gaithersburg, MD). Tonsil B cells were cultured in 96-well flat-bottom microtiter plates (Costar, Cambridge, MA) at a concentration of 100.000 cells/well in RPMI 1640 supplemented with 10% FCS at 37°C in a 5% CO, atmosphere. B cells were stimulated with various combinations of CD40 MoAb ((328-5 MoAb, kindly provided by Dr E. Clark, University of Washington, Seattle, WA), interleukin-4 (IL-4; Genzyme, Cambridge, MA), IL-2 (Cetus Corp, Emeryville, CA), anti-IgM (4B8 MoAb, kindly provided by Dr E. Clark), HB22.7, or CD22.5 MoAb. Each experimental condition was done in triplicate. B cells were cultured for 3 days and 1 pCu ['HI-thymidine was added over the last 18 hours of the culture period. The cells were procured and thymidine incorporation into DNA measured by standard scintillation counting. Similar cultures were performed in 96-well round-bottom plates (Costar) and assayed for thymidine incorporation as described above. Ig secretion was assessed by measuring IgG and IgM levels in culture supernatants derived from B-cell cultures established similarly to those used for measuring B-cell proliferation except that the cultures were allowed to continue for 7 days. The IgG and IgM levels were determined by ELISA as previously described.24 Several of the proliferation assays were also done in the presence of CDw32-transfected L cells as previously described." The costimulation assays were performed as Briefly, purified tonsil B cells were stimulated with Staphylococcus aureus Cowan strain I (SAC) for 24 hours, washed, and irradiated with 5,000 rads. The stimulated and irradiated tonsil B cells (200,000 cells/well) were cocultured with tonsil T cells (300,000 celldwell) in the presence of CD3 MoAb (1:10,000 dilution of ascites) in the presence or absence of HB22.7 or CD22.S MoAb. The cultures were allowed to Antibodies andpow cytometry.
Cell culture and assays.
proceed for 3 days before measuring thymidine incorporation into DNA as described above. The blot was stripped and sequentially reprobed with rabbit anti-SH-PTPlC (Upstate Biotechnology ) and rabbit anti-p53/561yn (Upstate Biotechnology) using the manufacturer's recommendations. CD22 levels in the immunoprecipitates were assayed by immunoblotting with the rabbit anti-CD22 antibody derived against a Cterminal peptide (1:200 dilution of antisera). All the immunoblots were reacted with a goat-antirabbit or sheep-antimouse antibodies conjugated to HRP (Amersham, Buckinghamshire, UK). All signals were detected by enhanced chemiluminescence (ECL, Amersham).
RESULTS

Immunoprecipitations and immunoblotting.
Engagenzent of CD22 induces tonsil B-cell proliferation that is augmented by cytokines or CD40. Several CD22 MoAbs block the interaction of CD22 with its ligand(s) on lymphocytes, erythrocytes, or neutrophil^.'.^ In the present experiments we compared the ab es of two isotypematched MoAbs, HB22.7 (a blocking MoAb) and CD22.5 (a nonblocking MoAb), to directly stimulate B-cell proliferation and to costimulate B-cell proliferation with cytokines or CD40. The addition of the HB22.7 MoAb to B-cell cultures increased thymidine incorporation approximately sixfold over background while the addition of the CD22.5 MoAb had no appreciable effect (Fig 1) . In the cytokine costimulatory experiments, the addition of 10 U of IL-2 significantly enhanced the response to HB22.7 (approximately threefold above HB22.7 alone), but not to CD22.5. A small costimulatory effect with CD22.5 and IL-2 occurred at the higher concentrations of IL-2 tested (Fig 2A) . HB22.7 and 100 U/ mL of IL-4 also costimulated B-cell proliferation (approximately twofold above HB22.7 alone), although less efficiently than did HB22.7 and IL-2 ( Fig 2B) . IL-10 failed to costimulate with either HB22.7 or CD22.5 MoAb (data not shown). In an attempt to more efficiently crosslink CD22 and to reduce the potential for Fc receptor binding, several assays were done in the presence of CDw32-transfected L cells. This resulted in a marginal (-10% to 20%) increase in proliferation compared to the B cell stimulated with HB22.7 alone (data not shown).
Because the interaction of CD40 with CD40 ligand is
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All the previously described experiments used flat-bottom culture plates to reduce cell-cell interactions. To determine whether increased B-cell to B-cell interactions might modulate the response to the HB22.7 MoAb, we cultured purified tonsil B cells in round bottom plates in the presence of similar concentrations of HB22.7 or CD22.5 MoAb. Not surprisingly, the background level of thymidine incorporation increased in the round-bottom plate cultures. While blocking any potential CD22/CD22L interactions by adding the MoAb HB22.7 to the round-bottom culture wells, we simultaneously stimulated B lymphocytes by engaging CD22. The overall result was a significant augmentation in B-cell proliferation (Fig 3B) . The fold increase in thymidine incorporation over background was similar in the roundand flat-bottom plates. CD22.5 had little effect under either culture condition (Fig 3B) . (Fig 2C) . Culturing B cells with increasing concentrations of the MoAb HB22.7 in the presence of optimal concentrations of IL-2, IL-4, or CD40 MoAb showed that the highest concentration of HB22.7 MoAb tested, 10 pg/ mL, gave the best costimulatory response (data not shown). Thus, the engagement of CD22 with the HB22.7 MoAb and either cytokines or CD40 MoAb triggers B-cell proliferation in a concentration-dependent manner. In contrast, the MoAb For of IL-2 to HB22.7 we detected moderate levels of IgG and low levels of IgM in the culture supernatant compared to stimulation with the isotype-matched control H1F6 (Fig 4) . While the HB22.7 MoAb plus IL-2 induced higher levels of Ig secretion than CD22.5 plus IL-2, the difference was less striking than we had observed in the proliferative studies. The prolonged culture period required to assay Ig production may explain the ability of CD22.5 to trigger an increase in Ig production despite inefficient signaling.
HB22.7 and CD22.5 differ in their abilities to trigger CD22 tyrosine phosphorylation and the association of CD22 withp53/561yn and SH-PTPI C.
The marked functional differences between the two CD22 antibodies prompted us to compare their abilities to trigger CD22 tyrosine phosphorylation and to trigger the association with downstream effectors. Purified tonsilar B cells or RAMOS cells, a B-cell line previously used to study signal transduction through CD22, were treated with HB22.7 or CD22.5 MoAb immobilized on goat-antimouse Ig magnetic beads. At various time points we immunoprecipitated CD22, size fractionated the immunoprecipitates via SDS-PAGE, and immunoblotted with an antiphosphotyrosine MoAb. HB22.7 MoAb stimulated more CD22 tyrosine phosphorylation than did CD22.5 MoAb in purified tonsilar B cells (Fig 5A) . Stripping and reprobing with anti-CD22 polyclonal antisera prepared with a C-terminal peptide verified that all immunoprecipitates contained nearly equivalent levels of CD22 (Fig 5B) . In similar experiments with RAMOS cells, HB22.7 stimulated more tyrosine phosphorylation of CD22 than did CD22.5 ( Fig 6) . Next, we examined for the presence of two downstream effectors known to associate with CD22, the src kinase p53/561ynzZa and the tyrosine phosphatase SH-PTPlC.32-34 Reprobing the same filter with antisera against anti-p53/561yn or SHPTPlC showed higher levels of both proteins in the CD22 immunoprecipitates prepared from HB22.7 stimulated cells than from the CD22.5 stimulated cells (Fig 6) . Again, stripping and reprobing with an anti-CD22 antisera verified that the immunoprecipitates contained nearly equivalent levels of CD22 (Fig 6) . Although these experiments were performed using digitonin lysates, similar results were found with NP-40 lysates (data not shown). thymidine incorporation 25% to 30% in four separate experiments (Fig 7) . In contrast, the nonblocking MoAb CD22.5 failed to modulate thymidine incorporation. The addition of either antibody to CD3 MoAb-stimulated T cells in the absence of B cells did not alter thymidine incorporation (data not shown). These data provided evidence that blocking CD22lCD22L interactions impairs T-cell activatiodproliferation.
Blocking CD22KD22L interactions inhibits T-cell prolq-
DISCUSSION
CD22 crosslinking triggers an amplifiable stimulatory signal for B lymphocytes. The CD22 MoAb HB22.7 directly stimulated B-cell proliferation, costimulated B-cell proliferation with anti-Ig, cytokines, or CD40. and induced B-cell Ig production with IL-2. The HB22.7 MoAb that blocks the interactions between CD22 and its ligand(s) had potent agonist activity while the CD22.5 MoAb that does not block had significantly less activity. These functional differences correlated with differences in amount of CD22 tyrosine phosphorylation induced and the association of p531561yn and SH-FTPIC with CD22.
CD22-CD22L interactions likely occur during primary The superiority of the HB22.7 versus CD22.5 MoAb in stimulating or costimulating B-cell proliferation likely results from differing abilities to trigger CD22 tyrosine phosphorylation and to recruit downstream effectors. We previously showed that p53/561yn associates with CD22 following CD22 crosslinking2'" and here show that SHPTPlC also rapidly associates. Considerable evidence supports a critical role for p53/561yn in B-lymphocyte signal transduction pathways. Besides its association with the CD22, it also has been found to associate with the B-cell antigen receptor complex and with the CD19/CD21 comIn contrast to the positive effects of p53/561yn, recent evidence indicates that SH-FTP1 C negatively regulates signal transduction pathway^."'^ However, despite its more potent stimulatory effects, HB22.7 crosslinking resulted in more SH-PTPlC associated with CD22 than did CD22.5 crosslinking. These data suggest that a balance between the positive and negative effectors recruited dictates the outcome of receptor engagement (see below).
Several recent reports have shown that SH-PTPlC associates with CD22 after crosslinking of the antigen receptor."-74 SH-PTP1C contains two SH-2 domains at its amino terminus and a carboxyl terminus tyrosine phosphatase catalytic domain. [43] [44] [45] The recognition that motheaten (me) and viable motheaten (vme) mice have loss-of-function mutations in this gene showed the importance of SH-PTPlC in hematopoiesis and immune f~n c t i o n .~~'~' The deficient mice develop a progressive inflammatory disease with abnormal hematopoiesis and elements of both immunodeficiency and autoimmunity. SH-PTPlC associates with and may dephosphorylate the erythropoietin, c-kit, and IL-3 receptor^.^"^"^^'^^^ In addition, coligation of the Fcy RIIB 1 with the B-cell antigen receptor complex leads to abortive signaling by recruiting SH-PTPIC into the complex.42 A likely role for SH-PTPlC is to counteract the positive effects of Src and Jak family kinases that also associate with these receptors. Similarly, the association of SH-PTPlC with CD22 likely counteracts the positive effects of p53/561yn, and perhaps p72syk and p85PI-3 kinase. Consistent with this idea, we found that p53/561yn, p72syk, and SH-PTPlC preferentially bind to a tyrosine phosphorylated peptide that spans the distal ITAMlike region in CD22, suggesting that tyrosine phosphorylated CD22 may be a substrate for SH-PTPIC resulting in dephosphorylation and receptor recycling (J. Tuscano, unpublished observation, October 1995). There is evidence to suggest that CD22 negatively regulates signaling via the antigen re~e p t o r '~ while our results indicate that engagement of CD22 can provide a stimulatory signal to B cells. Together these results suggest that engagement of the antigen receptor in the absence of CD22 crosslinking may impair signal transduction while stimulation of the antigen receptor in the context of CD22KD22L interactions augments signaling.
We have also shown that inhibition of CD22-CD22L engagement partially impairs T-cell activation in a costimulatory assay using CD3 MoAb and irradiated B cells. This contrasts with previously published experiments using a CD22 fusion protein that demonstrated costimulation of T cells with CD3 MoAb and the fusion protein suppressed Tcell proliferation.' Furthermore, crosslinking CD22L using the CD22 fusion protein blocked CD3 MoAb-induced increases in intracellular calcium and phosphorylation of phospholipase Cy 1 ." From these previous experiments, the inhibition of a CD22/CD22L interaction would have been predicted to enhance T-cell activation, rather than inhibit it as we observed. Although there are several potential explanations for these differences, perhaps the most likely is that the MoAb blocking experiments reported in this study are in the context of cell-cell interactions whereas the fusion protein experiments only examine the consequences of crosslinking CD22Ls and CD3. The engagement of other surface molecules such as CD2-LFA-I and B7-CD28 may significantly alter the consequences of the CD22L-CD22 interaction. Indeed, the inhibitory effect of HB22.7 on T-cell COstimulation may result from reducing B -T-cell collaboration by decreasing interactions with other cell-surface stimulatory For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From
